Sign in
Stories
Bioptimus Launches AI Startup for Biotechnology
Share
4P-Pharma Secures €15 Million Funding
AI Advancements Impact Healthcare and Fi...
AI Innovations and Funding Boosts
7wireVentures' $217M Health Fund Launch
AI Boosts Healthcare Efficiency
AI Startup Xaira Revolutionizes Drug Dev...
Overview
API
Executives from Owkin, a French AI drug discovery unicorn, have launched a new startup, Bioptimus, to develop an LLM for biotechnology. The company aims to raise a €20m seed round and has secured funding above that target. Bioptimus is led by Owkin's chief R&D officer and ex-Google researcher Jean-Philippe Vert, along with senior Owkin executives David Cahané and Eric Durand. The company plans to focus on simplifying complex biomedical data for AI technologies, with potential applications in other industries. Owkin, a partner in providing data for Bioptimus’s LLM, is HQ'd in Paris and the US.
Ask a question
How does the partnership between Owkin and Bioptimus contribute to the advancement of AI in biotechnology?
How might the development of an LLM for biotechnology impact the field of drug discovery?
What are the potential implications of Bioptimus's focus on simplifying complex biomedical data for AI technologies?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage